4DMT Appoints Uneek Mehra as Chief Financial and Business Officer
September 12, 2023 16:05 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company harnessing the power of directed...
4DMT to Participate in Upcoming Investor Conferences
September 07, 2023 16:05 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, 4DMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for...
4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD
September 07, 2023 08:00 ET
|
4D Molecular Therapeutics, Inc.
First patient has been enrolled in the Dose Confirmation stage (n=18) of the Phase 2 SPECTRA clinical trial for intravitreal 4D-150 in patients with diabetic macular edema First patient enrolled in...
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
June 01, 2023 08:00 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic...
4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting
May 24, 2023 08:00 ET
|
4D Molecular Therapeutics, Inc.
Interim data to be presented in an oral presentation by Dr. Jennifer L. Taylor-Cousar, MD, MSCS at the 2023 ECFS Annual Meeting in Vienna, Austria on Thursday, June 8, 2023 at 5:00 p.m. CET (11:00...
4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
May 11, 2023 08:00 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted...
4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
May 10, 2023 16:05 ET
|
4D Molecular Therapeutics, Inc.
Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration (wet AMD) at the 2023 ARVO Annual MeetingOn track for completion of...
4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 09, 2023 16:05 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic...
4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023
April 27, 2023 07:00 ET
|
4D Molecular Therapeutics, Inc.
Intravitreal 4D-150 was well-tolerated with no inflammation in 14 of 15 patients and only trace mixed cells at a single timepoint in one patient; no dose-limiting toxicities, treatment-related serious...
Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H
April 24, 2023 08:00 ET
|
Fortress Biotech, Inc.
MIAMI, April 24, 2023 (GLOBE NEWSWIRE) -- Aevitas Therapeutics, Inc. (“Aevitas”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company, and 4D Molecular Therapeutics (Nasdaq:...